Sector News

Novartis CEO sees tougher U.S. drug pricing over next 3-5 years

October 26, 2016
Life sciences

Novartis expects a more difficult pricing environment for drugs in the United States in the years ahead, its chief executive told a results conference call on Tuesday.

“We expect pricing to become more difficult in the U.S. over the next three to five years,” Joe Jimenez said.

Both major U.S. presidential candidates have cited concern about drug pricing.

Swiss rival Roche’s Chief Executive Severin Schwan had said last week he did not see a “fundamental change” in U.S. price pressure after the Nov. 8 presidential election, regardless of which candidate wins.

Jimenez also said Novartis was on track to reach $1 billion sales in biosimilars this year. He said Novartis would focus on bolt-on acquisitions and a larger deal would be considered only if it was “very attractive” to Novartis, he said.

By Silke Koltrowitz and Paul Arnold

Source: Reuters

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach